51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Tejara Capital Ltd

Tejara Capital Ltd purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 51,967 shares of the company’s stock, valued at approximately $381,000.

A number of other institutional investors and hedge funds have also made changes to their positions in VIR. SBI Securities Co. Ltd. acquired a new stake in shares of Vir Biotechnology in the 4th quarter valued at about $60,000. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 31.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after buying an additional 1,999 shares in the last quarter. KBC Group NV boosted its holdings in Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after buying an additional 5,177 shares in the last quarter. CIBC Asset Management Inc acquired a new position in Vir Biotechnology in the 4th quarter worth approximately $74,000. Finally, Captrust Financial Advisors purchased a new stake in Vir Biotechnology in the 3rd quarter worth approximately $118,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VIR shares. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a report on Friday, February 28th. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. JPMorgan Chase & Co. upped their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research report on Thursday, February 27th. Finally, Leerink Partners upped their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.67.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $7.01 on Tuesday. The firm’s fifty day moving average is $9.49 and its 200-day moving average is $8.42. Vir Biotechnology, Inc. has a 52 week low of $6.56 and a 52 week high of $14.45. The firm has a market cap of $961.37 million, a P/E ratio of -1.79 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. The company had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. As a group, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the sale, the director now directly owns 708,295 shares in the company, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,859 shares of company stock worth $326,458 over the last quarter. 15.60% of the stock is currently owned by company insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).